Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 5/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998542 | 0.93 | KIF11 (0.43) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL998717 | 0.90 | ABCB1 (0.50) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL996744 | 0.90 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL999416 | 0.87 | KIF11 (0.52) | KDM4EKIF11ABCB1ABCG2TP53 | |
| SCHEMBL997310 | 0.86 | ABCB1 (0.44) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL997546 | 0.86 | ABCG2 (0.53) | KDM4EKIF11ABCB1ABCG2TP53 | |
| SCHEMBL996837 | 0.86 | ABCG2 (0.50) | MEN1KMT2APOLBKIF11ABCB1 | |
| SCHEMBL997421 | 0.85 | NPC1 (0.45) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL2031342 | 0.85 | KIF11 (0.40) | KIF11 | |
| SCHEMBL997890 | 0.85 | KIF11 (0.49) | MEN1KMT2AKDM4EKIF11ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105415-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8952158-B2 | Tricyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-1829874-B1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20130252993-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| US-8476293-B2 | Tricyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-7964726-B2 | 1-(1,3-benzodioxol-5-yl)-N-(3,5-dimethylphenyl)-1,9-dihydrospiro[ beta -carboline-4,1'-cyclopropane]-2(3H)-carboxamide; mitochondrial benzodiazepine receptor modulator; digestive system disease caused by stress: irritable bowel syndrome, ulcerative colitis, or Crohn's disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1829874-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | ALDH1A1 864/4885MEN1 2538/4885KMT2A 2969/4885 |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | ALDH1A1 1422/4885MEN1 1017/4885KMT2A 2539/4885 |
| US-20150105415-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | ALDH1A1 864/4885MEN1 2538/4885KMT2A 2969/4885 |
| US-20130252993-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | ALDH1A1 864/4885MEN1 2538/4885KMT2A 2969/4885 |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | SI, ALPI, SLC10A2 | ALDH1A1 869/4885MEN1 2425/4885KMT2A 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.